Twist Bioscience Company Insiders
| TWST Stock | USD 43.09 0.95 2.16% |
Twist Bioscience's insiders are aggressively selling. The analysis of the overall insider sentiment regarding Twist Bioscience Corp suggests that vertually all insiders are panicking. Twist Bioscience employs about 919 people. The company is managed by 14 executives with a total tenure of roughly 37 years, averaging almost 2.0 years of service per executive, having 65.64 employees per reported executive.
| Emily Leproust CEO President CEO, Director |
| Patrick Finn President Vice President of Sales and Marketing |
Twist Bioscience's Insider Buying Vs Selling
0
Selling | Buying |
Latest Trades
| 2024-05-03 | Emily M Leproust | Disposed 4163 @ 37.13 | View | ||
| 2024-04-23 | Patrick John Finn | Disposed 2174 @ 30.12 | View | ||
| 2024-04-09 | Adam Laponis | Disposed 556 @ 33.16 | View | ||
| 2024-04-02 | Emily M Leproust | Disposed 1132 @ 32.74 | View | ||
| 2024-03-20 | Paula Green | Disposed 200 @ 33.52 | View | ||
| 2024-03-14 | Dennis Cho | Disposed 93 @ 34.6 | View | ||
| 2024-03-06 | Robert F Werner | Disposed 181 @ 37.43 | View | ||
| 2024-02-08 | Robert Chess | Disposed 4110 @ 34.98 | View |
Monitoring Twist Bioscience's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Twist |
Twist Bioscience's Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Twist Bioscience's future performance. Based on our forecasts, it is anticipated that Twist will maintain a workforce of slightly above 920 employees by June 2024.Twist Bioscience Management Team Effectiveness
The company has return on total asset (ROA) of (0.1563) % which means that it has lost $0.1563 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.304) %, meaning that it created substantial loss on money invested by shareholders. Twist Bioscience's management efficiency ratios could be used to measure how well Twist Bioscience manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.3 in 2024. Return On Capital Employed is likely to drop to -0.29 in 2024. Non Current Liabilities Total is likely to gain to about 90.3 M in 2024, whereas Total Current Liabilities is likely to drop slightly above 45.4 M in 2024.Common Stock Shares Outstanding is likely to drop to about 39.9 M in 2024. Net Loss is likely to gain to about (186.3 M) in 2024
Twist Bioscience Workforce Comparison
Twist Bioscience Corp is rated below average in number of employees category among related companies. The total workforce of Health Care industry is at this time estimated at about 148,837. Twist Bioscience maintains roughly 919 in number of employees contributing less than 1% to equities under Health Care industry.
The company has Profit Margin (PM) of (0.69) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.65) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.65. Twist Bioscience Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Twist Bioscience insiders, such as employees or executives, is commonly permitted as long as it does not rely on Twist Bioscience's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Twist Bioscience insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
| Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
|---|---|---|---|---|---|
| 2024-03-01 | 0.36 | 9 | 25 | 115,705 | 24,566 |
| 2023-12-01 | 0.4643 | 13 | 28 | 503,123 | 40,642 |
| 2023-09-01 | 0.2174 | 5 | 23 | 156,355 | 15,695 |
| 2023-06-01 | 0.1852 | 5 | 27 | 102,044 | 29,115 |
| 2023-03-01 | 0.1951 | 8 | 41 | 88,110 | 22,862 |
| 2022-12-01 | 0.4706 | 8 | 17 | 163,316 | 19,020 |
| 2022-09-01 | 0.0698 | 3 | 43 | 19,014 | 64,070 |
| 2022-06-01 | 0.2105 | 8 | 38 | 24,321 | 52,961 |
| 2022-03-01 | 0.4286 | 21 | 49 | 77,590 | 43,608 |
| 2021-12-01 | 0.3967 | 48 | 121 | 267,046 | 314,943 |
| 2021-09-01 | 0.265 | 31 | 117 | 125,314 | 418,366 |
| 2021-06-01 | 0.2727 | 30 | 110 | 83,065 | 600,326 |
| 2021-03-01 | 0.2692 | 42 | 156 | 151,144 | 810,511 |
| 2020-12-01 | 0.1888 | 27 | 143 | 188,811 | 593,487 |
| 2020-09-01 | 0.375 | 36 | 96 | 536,786 | 3,029,295 |
| 2020-06-01 | 0.1163 | 5 | 43 | 26,258 | 256,134 |
| 2020-03-01 | 0.5349 | 23 | 43 | 140,502 | 296,472 |
| 2019-12-01 | 0.5161 | 32 | 62 | 609,579 | 390,162 |
| 2019-09-01 | 0.2436 | 19 | 78 | 109,760 | 233,872 |
| 2019-06-01 | 4.0 | 4 | 1 | 41,067 | 0.00 |
| 2018-12-01 | 0.7647 | 39 | 51 | 12,969,273 | 15,821,221 |
Twist Bioscience Notable Stakeholders
A Twist Bioscience stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Twist Bioscience often face trade-offs trying to please all of them. Twist Bioscience's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Twist Bioscience's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Emily Leproust | President CEO, Director | Profile | |
| Patrick Finn | Vice President of Sales and Marketing | Profile | |
| Paula Green | Vice President of Human Resources | Profile | |
| Dennis Cho | General VP | Profile | |
| Robert Werner | VP Officer | Profile | |
| William Banyai | GM Development | Profile | |
| Kevin Yankton | VP Officer | Profile | |
| Chet Gandhi | Chief Officer | Profile | |
| Siyuan Chen | Chief Officer | Profile | |
| Aaron Sato | Chief Officer | Profile | |
| James Thorburn | Chief Officer | Profile | |
| Erin Smith | Sr Policy | Profile | |
| Adam Laponis | Chief Officer | Profile | |
| Angela Bitting | Chief Affairs | Profile |
About Twist Bioscience Management Performance
The success or failure of an entity such as Twist Bioscience Corp often depends on how effective the management is. Twist Bioscience management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Twist management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Twist management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.29) | (0.30) | |
| Return On Capital Employed | (0.28) | (0.29) | |
| Return On Assets | (0.24) | (0.25) | |
| Return On Equity | (0.38) | (0.36) |
The data published in Twist Bioscience's official financial statements usually reflect Twist Bioscience's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Twist Bioscience Corp. For example, before you start analyzing numbers published by Twist accountants, it's critical to develop an understanding of what Twist Bioscience's liquidity, profitability, and earnings quality are in the context of the Biotechnology space in which it operates.
Please note, the presentation of Twist Bioscience's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Twist Bioscience's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Twist Bioscience's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Twist Bioscience Corp. Please utilize our Beneish M Score to check the likelihood of Twist Bioscience's management manipulating its earnings.
Twist Bioscience Workforce Analysis
Traditionally, organizations such as Twist Bioscience use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Twist Bioscience within its industry.Twist Bioscience Manpower Efficiency
Return on Twist Bioscience Manpower
| Revenue Per Employee | 266.7K | |
| Revenue Per Executive | 17.5M | |
| Net Loss Per Employee | 222.7K | |
| Net Loss Per Executive | 14.6M | |
| Working Capital Per Employee | 381.9K | |
| Working Capital Per Executive | 25.1M |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Twist Bioscience Corp. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state. You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Complementary Tools for Twist Stock analysis
When running Twist Bioscience's price analysis, check to measure Twist Bioscience's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Twist Bioscience is operating at the current time. Most of Twist Bioscience's value examination focuses on studying past and present price action to predict the probability of Twist Bioscience's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Twist Bioscience's price. Additionally, you may evaluate how the addition of Twist Bioscience to your portfolios can decrease your overall portfolio volatility.
| Stocks Directory Find actively traded stocks across global markets | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios |
Is Twist Bioscience's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Twist Bioscience. If investors know Twist will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Twist Bioscience listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.36) | Revenue Per Share 4.834 | Quarterly Revenue Growth 0.251 | Return On Assets (0.16) | Return On Equity (0.30) |
The market value of Twist Bioscience Corp is measured differently than its book value, which is the value of Twist that is recorded on the company's balance sheet. Investors also form their own opinion of Twist Bioscience's value that differs from its market value or its book value, called intrinsic value, which is Twist Bioscience's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Twist Bioscience's market value can be influenced by many factors that don't directly affect Twist Bioscience's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Twist Bioscience's value and its price as these two are different measures arrived at by different means. Investors typically determine if Twist Bioscience is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Twist Bioscience's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.